



LEUKEMIA &
LYMPHOMA
SOCIETY®

Therapy Acceleration Program®

Current and Former Portfolio Assets
Beyond Blood Cancer Development



Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3
Mavorixafor	CXCR4 small molecule	WHIM Syndrome				
MILs +/- Nivolumab	T Cell Therapy	NSCLC				
Rigosertib + Nivolumab	RAS pathway small molecule	KRAS ⁺ NSCLC				
PVX-410 + Durvalumab	vaccine	Triple Negative Breast Cancer				
Fimepinostat	HDAC/PI3K small molecule	Solid tumors (pediatric)		IST		

IST: investigator-sponsored trial

Updated October 2020